These newer agents appear to be effective in the treatment of bipolar disorder, especially for those patients with rapid cycling, dysphoric or mixed mania, or neurologic abnormalities.

More recently, it has been explored as an adjunctive treatment for bipolar 1 depression. Some evidence indicates that modafinil can significantly improve depressive symptoms and functioning in ...

Bipolar disorder has potential links to memory changes during and after depressive or manic episodes. Learn how states and ...

They cited 4 myths about bipolar depression treatment that have either been disproved or are not supported by current evidence: (1) bipolar disorder is not a lifelong illness and episodes only ...

Being aware of these factors is important for both identifying and treating bipolar. Treatment for Bipolar Disorder Because bipolar disorder is a recurrent illness, long-term treatment is necessary.

These reports can also help a healthcare provider distinguish between bipolar 1 vs. 2— variations in the disease that can ...

New Form of Repetitive Magnetic Brain Stimulation Reduces Treatment Time for Bipolar Disorder July 10, 2024 — A potential new treatment for bipolar disorder (BP) that significantly shortens ...

Figure 1: Clinical features, genetic determinants, and treatment response overlap between bipolar disorder and schizophrenia. The most important goals of genetic studies are to provide ...

Reading memoirs and nonfiction about bipolar disorder helps connect with those living with this brain-based condition, ...

His focus on the PVT stems from evidence found more than 20 years ago that mitochondria in the brain were dysfunctional in people who had experienced bipolar disorder 1. His early studies with ...

Bipolar disorder can lead to risky behavior, damaged relationships and careers, and even suicidal tendencies if it's not treated. Doctors don't completely understand the causes of bipolar disorder ...

AbbVie will buy Aliada Therapeutics for $1.4 billion in cash, it said on Monday, gaining access to the privately held therapy developer's Alzheimer's disease candidate as the U.S. drugmaker increases ...